MA01.03 Interim Safety Analysis of the Phase IB Trial of SBRT to All Sites of Oligometastatic NSCLC Combined with Durvalumab and Tremelimumab
JOURNAL OF THORACIC ONCOLOGY（2019）
关键词
Oligometastatic NSCLC,SBRT,immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要